ArticleBMC neurology2025
The role of immune cell phenotypes and metabolites in the risk of ischemic stroke: a Mendelian randomization-based mediation analysis.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIschemic stroke (IS) occurs when a blood clot obstructs a blood vessel supplying blood to the brain, leading to brain tissue damage due to insufficient oxygen and nutrients. The roles of immune cells and metabolites in IS are increasingly recognized, yet their specific mechanisms remain unclear.
methodsThis study conducted a comprehensive statistical analysis to explore the relationships between immune cell phenotypes, metabolite levels, and IS. We utilized methods such as inverse variance weighted (IVW), weighted median, and MR Egger to ensure robust results. Sensitivity analyses were performed to confirm the absence of significant heterogeneity or pleiotropy.
resultsWe identified several immune cell phenotypes significantly associated with IS. Notably, IgD + CD24 + AC showed a positive association with IS (OR = 1.045601, p = 0.011562), while CD62L- HLA DR + + monocyte AC demonstrated a negative association (OR = 0.948673, p = 0.005415). Among metabolites, adenosine 5'-monophosphate (AMP) to cysteine ratio was positively associated with IS (OR = 1.083144, p = 0.000310), whereas xanthurenate levels were negatively associated (OR = 0.926100, p = 0.001614). Mediation analysis revealed a significant mediating effect of acetylcarnitine levels on the relationship between IgD + CD24 + AC and IS, with an estimated mediation effect of 0.00606 (p = 0.036834077).
conclusionOur study highlights the crucial roles of specific immune cell phenotypes and metabolites in IS, suggesting their potential as novel therapeutic targets or biomarkers. The mediation analysis underscores the complex interactions between immune cells and metabolites in IS, providing valuable insights for future research. These findings pave the way for further exploration of the pathophysiological mechanisms and therapeutic strategies for IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.